Raymond Hill, Former IMS and InVentiv Health Executive, Joins Medivo’s Board of Directors

Share Article

Appointment is effective November 12, 2014; expands Medivo's Board of Directors to six

Medivo, Inc.
Medivo is discovering actionable insights that can be used to treat the right patients with the right drugs at the right time.

Medivo, Inc., a leader in lab data analytics, today announced that Raymond Hill has been elected to Medivo’s board of directors. As President of InVentiv Health Clinical, Mr. Hill was instrumental in driving EBITDA growth, reducing attrition, securing key strategic partnerships, and re-positioning the company. As President of IMS Consulting and Services, Mr. Hill spearheaded work in portfolio strategy, pricing and market access, launch excellence, managed markets, sales force effectiveness, and commercial outsourcing. Mr. Hill also served as the CEO of Pharmaceutical Product Development Inc.

According to Sundeep Bhan, CEO of Medivo, Mr. Hill’s expertise will be an invaluable resource to the company. “I’m delighted that Ray will be joining our board of directors. His experience managing both clinically oriented and data oriented firms in the healthcare space will serve us well. I look forward to his counsel on matters relating to healthcare data analytics, understanding pharma needs, improving patient care and the convergence of diagnostics, data and therapy selection.”

Mr. Hill’s appointment expands the Board to 6 directors. Mr. Hill joins the following directors:

● Gary Kurtzman, MD, Managing Director, Safeguard Scientifics
● David Stack, President, CEO and Director of Pacira Pharmaceuticals
● Joseph B. Volpe III, Managing Director, Merck Global Health Innovation, Global Health Innovation Fund LLC
● Jason Bhan, MD, Chief Medical Officer, Medivo, Inc.
● Sundeep Bhan, CEO, Medivo, Inc.

“I am excited to be joining the board and advising the team at this most interesting time in healthcare”, said Mr. Hill. “Medivo is doing really innovative things in commercializing lab data. With access to over 30 million patients and over 100 million lab test results, Medivo is discovering actionable insights that can be used to treat the right patients with the right drugs at the right time.”

Mr. Hill is the Executive Chairman of Corrona LLC. He also serves on the Board of IntelliCell Biosciences, Inc., and the not-for-profit organization RowNY. He is a graduate of Cornell University and received a Masters degree from Duke University.

Mr. Hill’s appointment is effective November 12, 2014.

About Medivo
Medivo unlocks the power of lab data to better inform treatment decisions and improve health outcomes. Medivo’s clinical data experts extract proprietary insights from the Medivo Lab Value Exchange™ (LVX™), an anonymized patient level clinical database of more than 30 million patients. Medivo helps deliver on the promise of precision medicine by providing decision support on the use of targeted therapeutics. Medivo enables life science companies to build clinical intelligence to optimize their sales and marketing initiatives, while enabling our clinical lab partners to realize the full value of their data assets. Founded in 2010 by healthcare entrepreneurs, Medivo’s investors include Safeguard Scientifics, Inc. (NYSE:SFE) and Merck Global Health Innovation Fund (GHIF). For more information, visit http://www.medivo.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Allison Keeley
Medivo, Inc.
+1 917-945-8502
Email >
Follow us on
Visit website